Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) EBITDA (2017 - 2026)

Lexaria Bioscience's EBITDA history spans 10 years, with the latest figure at -$1.4 million for Q1 2026.

  • Quarterly results put EBITDA at -$1.4 million for Q1 2026, up 49.11% from a year ago — trailing twelve months through Feb 2026 was -$9.5 million (changed 0.15% YoY), and the annual figure for FY2025 was -$12.0 million, down 105.54%.
  • EBITDA for Q1 2026 was -$1.4 million at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$674537.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
  • The 5-year median for EBITDA is -$1.8 million (2022), against an average of -$1.9 million.
  • The sharpest move saw EBITDA crashed 316.35% in 2025, then surged 49.11% in 2026.
  • Year by year, EBITDA stood at -$1.8 million in 2022, then soared by 33.09% to -$1.2 million in 2023, then crashed by 130.38% to -$2.7 million in 2024, then skyrocketed by 40.86% to -$1.6 million in 2025, then rose by 10.71% to -$1.4 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$1.4 million, -$1.6 million, and -$2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.